Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Sawai Recalls Antibiotic Cefdinir Manufactured by Choseido, 4 Other APIs
Sawai Pharmaceutical said on May 23 that it has launched a voluntary recall for the oral cephalosporin antibiotic cefdinir due to an unauthorized production method used at contract manufacturer Choseido Pharmaceutical. Subject to the Class II recall is Cefdinir Tablets…
To read the full story
Related Article
- Choseido’s Kawauchi Plant Suspended for 1 Month on GMP Violation
March 28, 2025
- Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
- Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
- Choseido Contract Manufactured Cephem Antibiotics for 8 Firms
June 14, 2024
- Choseido Violates GMP Once Again with Cefdinir, More Cases Being Probed
May 27, 2024
BUSINESS
- Sanofi Japan Bets on Beyfortus Track Record with NIP Inclusion in Sight
November 11, 2026
- Vital KSK’s Medleap Pivots to In-House Drug Filings, Eyes 2029 Launch
November 10, 2026
- Alfresa, Partners Seal Share Deal to Formalize Biosimilar JV
November 10, 2026
- Japan Ethical Drug Sales Rise 3.5% in September: Crecon
November 10, 2026
- Shionogi Grabs Japan Nod for Updated COVID Vaccine
November 10, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…